drugset / Trial / NCT05057468
Second-line Treatment of Primary Autoimmune Hemolytic Anemia
RandomizedParallel-groupOpen-labelTreatment
Summary
the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.
Timeline
- Start
- 2021-10-20
- Primary completion
- 2026-11-01
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 2.5 mg | Oral |
| Subject | Cyclosporine | Peptide | 5 mg | Oral |
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | — |